APTO Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Company profile
Ticker
APTO
Exchange
Website
CEO
William Rice
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.), IMUTEC PHARMA INC, LORUS THERAPEUTICS INC
SEC CIK
Corporate docs
APTO stock data
()
News
64 Biggest Movers From Yesterday
25 Mar 21
Aptose Biosciences Stock Trades Higher After Q4 Earnings: Technical Levels To Watch
24 Mar 21
Mid-Afternoon Market Update: Dow Surges 270 Points; GameStop Shares Drop After Q4 Earnings
24 Mar 21
12 Health Care Stocks Moving In Wednesday's Intraday Session
24 Mar 21
Mid-Day Market Update: Crude Oil Rises 3.5%; Second Sight Medical Products Shares Plunge
24 Mar 21
Press releases
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
8 Apr 21
Thinking about buying stock in Dolphin Entertainment, Hall of Fame Resort & Entertainment, Aptose Biosciences, Cinedigm, or Brainstorm Cell Therapeutics?
24 Mar 21
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23 Mar 21
Aptose Biosciences, Inc. to Host Earnings Call
23 Mar 21
Aptose Expands Senior Leadership Team
16 Mar 21
Investment data
Securities sold
Number of investors
Calendar
23 Mar 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 117.39M | 117.39M | 117.39M | 117.39M | 117.39M | 117.39M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 4.92M | 4.65M | 3.45M | 2.82M |
| Cash used (since last report) | n/a | n/a | 17.54M | 16.57M | 12.3M | 10.07M |
| Cash remaining | n/a | n/a | 99.85M | 100.82M | 105.09M | 107.32M |
| Runway (months of cash) | n/a | n/a | 20.3 | 21.7 | 30.5 | 38.0 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Jan 21 | Ashe Carol Gail | Director Stock Option Common Shares | Grant | Aquire A | No | No | 4.37 | 50,000 | 218.5K | 50,000 |
| 4 Jan 21 | Rafael Bejar | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 4.37 | 343,000 | 1.5M | 343,000 |
| 4 Jan 21 | Burger Denis R | Director Stock Option Common Shares | Grant | Aquire A | No | No | 4.37 | 50,000 | 218.5K | 50,000 |
| 4 Jan 21 | Chow Gregory K. | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 4.37 | 343,000 | 1.5M | 343,000 |
| 4 Jan 21 | Loewy Caroline M | Director Stock Option Common Shares | Grant | Aquire A | No | No | 4.37 | 50,000 | 218.5K | 50,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Competition
Viracta TherapeuticsManagement Discussion
- Net loss of $55.2 million for the year ended December 31, 2020 increased by approximately $28.9 million as compared with $26.3 million for the year ended December 31, 2019, primarily as a result of an increase of $19.1 million in stock-based compensation in the current period, a combined increase in program costs and related labor costs of approximately $9.8 million on our luxeptinib development program and higher cash-based general and administrative expenses of approximately $549 thousand. These expenses were partially offset by lower costs of $545 thousand on our APTO-253 development programs.
- R&D expenses increased by $12.5 million to $29.3 million for the year ended December 31, 2020 as compared with $16.8 million for the comparative period in 2019. Changes to the components of our R&D expenses presented in the table above are primarily as a result of the following activities:
- General and administrative expenses for the year ended December 31, 2020 were approximately $26.5 million as compared with $10.0 million for the comparative period in 2019, an increase of approximately $16.5 million. The increase was primarily as a result of the following:
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
Financial reports
10-K
2020 FY
Annual report
23 Mar 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
10 Mar 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K/A
2018 FY
Annual report (amended)
22 Apr 19
10-K/A
2018 FY
Annual report (amended)
12 Apr 19
Current reports
8-K
Departure of Directors or Certain Officers
26 Mar 21
8-K
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23 Mar 21
8-K
Regulation FD Disclosure
16 Mar 21
8-K
Aptose Presents Highlights from ASH and Corporate Update Event
7 Dec 20
8-K
Aptose Reports Results for the Third Quarter 2020
10 Nov 20
8-K
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
4 Nov 20
8-K
Regulation FD Disclosure
19 Oct 20
8-K
Aptose Reports Results for the Second Quarter 2020
5 Aug 20
8-K
Material Change Report
30 Jul 20
8-K
Aptose Announces Pricing of Public Offering of Common Shares
16 Jul 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Jul 20
424B5
Prospectus supplement for primary offering
14 Jul 20
424B5
Prospectus supplement for primary offering
5 May 20
424B2
Prospectus for primary offering
9 Jan 20
S-3
Shelf registration
27 Dec 19
424B5
Prospectus supplement for primary offering
17 Dec 19
424B5
Prospectus supplement for primary offering
16 Dec 19
424B5
Prospectus supplement for primary offering
30 May 19
424B5
Prospectus supplement for primary offering
29 May 19
424B5
Prospectus supplement for primary offering
24 May 19
Other
EFFECT
Notice of effectiveness
10 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
UPLOAD
Letter from SEC
5 Jan 20
EFFECT
Notice of effectiveness
26 Apr 19
CORRESP
Correspondence with SEC
22 Apr 19
UPLOAD
Letter from SEC
11 Apr 19
CORRESP
Correspondence with SEC
8 Apr 19
UPLOAD
Letter from SEC
3 Apr 19
CT ORDER
Confidential treatment order
10 Jul 18
EFFECT
Notice of effectiveness
10 Apr 18
Ownership
SC 13G/A
Aptose Biosciences / Consonance Capital Management ownership change
17 Feb 21
SC 13G/A
Aptose Biosciences / Consonance Capital Management ownership change
16 Feb 21
SC 13G/A
Aptose Biosciences / Consonance Capital Management ownership change
15 Feb 21
SC 13G
Aptose Biosciences / ORBIMED CAPITAL ownership change
12 Feb 21
SC 13G/A
Aptose Biosciences / Nantahala Capital Management ownership change
12 Feb 21
SC 13G/A
Aptose Biosciences / Wilson Donald R. Jr. ownership change
1 Feb 21
SC 13G/A
Aptose Biosciences / Abramson Herbert ownership change
15 Jan 21
4
Aptose Biosciences / Warren Whitehead ownership change
6 Jan 21
4
Aptose Biosciences / Mark D. Vincent ownership change
6 Jan 21
4
Aptose Biosciences / William G. Rice ownership change
6 Jan 21
Patents
APP
Utility
Combination Therapy with 2,3-DIHYDRO-ISOINDOLE-1-ONE Compounds and Methods for Treating Patients with Various Mutations
3 Jun 20
The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, alone or in combination with an anticancer agent, for the treatment of hematological cancers such as acute myeloid leukemia (AML).
APP
Utility
Fused Pyrimidine Compounds As BRD4 and JAK2 Dual Inhibitors and Methods for Use Thereof
25 Mar 20
The present invention relates to fused pyrimidine compounds, particularly pyrrolopyrimidine and thienopyrimidine compounds and derivatives thereof, pharmaceutical compositions thereof, and methods of inhibiting BRD4 and/or JAK2, as well as methods of treating various diseases and conditions, such as cancer and leukemia, with such compounds.
Transcripts
2020 Q4
Earnings call transcript
24 Mar 21
2020 Q3
Earnings call transcript
10 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
10 Mar 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
7 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
13 Mar 19
2018 Q3
Earnings call transcript
7 Nov 18
Reddit threads
$ATOS - Currently trading 45% under recent Direct Offering from $2.88 to $1.75
13 Apr 21
Expected Biotech News 13 April 2021 to 17 June 2021 and PDUFA List for 26 April 2021 to 15 June 2021
10 Apr 21
How often do we see run like EEIQ WAFU?
28 Mar 21
$APTO Shorts piled on yesterday after a big run up but now they gotta cover as the low float stock just had 3 analysts give it a “BUY” recommendation and a $9, $12 and $14 price target.
25 Mar 21
Great trading day!
24 Mar 21
Pennies list 3/24 💎🐒
24 Mar 21
Your Mom's Game Plan for March 24, 2021
24 Mar 21
Morning Update for Wednesday, 03/24/21
24 Mar 21
Easy pre market watch list 03/24
24 Mar 21
High Tide completes Smoke Cartel acquisition
24 Mar 21